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Abstract 
Introduction: Patients with right ventricular (RV) pacemakers are at 
increased risk of left ventricular (LV) systolic dysfunction (LVSD). We aimed to 
establish the prevalence, degree and associations of LVSD in patients with 
long term RV pacemakers listed for pulse generator replacement (PGR). 
Methods: All patients listed for PGR at Leeds General Infirmary were invited 
to attend for an assessment during which we recorded medical history, 
symptomatic status, medical therapy, date and indication of first implantation, 
the percentage of RV pacing (%RVP) and an echocardiogram. 
Results: We collected data on 491 patients. An LV ejection fraction <50% 
was observed in 40% of our cohort, however this was much higher (59%) in 
those with >80%RVP than in those with <80%RVP (22%)(p<0.0001). 
Multivariable analysis revealed %RVP, (but not complete heart block at 
baseline), serum creatinine and previous myocardial infarction to be 
independently related to the presence of LVSD. A model combining %RVP 
and previous myocardial infarction has a c-statistic of 0.74 for predicting 
LVSD. After a mean follow-up time of 668 days, 56 patients (12%) were dead 
or had been hospitalised for heart failure. In multivariable analysis, previous 
myocardial infarction and high %RVP were independently associated with a 
worse survival.  
Conclusions: Patients with RV pacemakers have a high prevalence of LVSD 
and this is greater in those exposed to more RV pacing. Those with LVSD and 
high amounts of RV pacing are at higher risk of hospitalisation or death. 
Simple variables can identify those patients who might benefit from a more 
comprehensive review.  
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Introduction 
The treatment of bradycardia by implantation of an artificial cardiac 
pacemaker is a routine procedure associated with extended longevity for 
those with atrio-ventricular (AV) block [1][2] and improved quality of life for 
patients with sick sinus syndrome.[3] However, long term right ventricular 
(RV) pacing is associated with adverse remodelling of the left ventricle,[4] 
which can contribute to or cause left ventricular systolic dysfunction 
(LVSD),[5] or overt heart failure.[6] In prospective studies of patients receiving 
standard RV pacemakers, subsequent hospitalisation for heart failure varies 
from 10% to 26%,[6][7] possibly, although not consistently,[8] related to the 
amount of RV pacing delivered,[6] and baseline features such as the 
presence of impaired left ventricular (LV)  function, atrial fibrillation and older 
age at implant [7][9] and paced QRS.[10] In a cross-sectional study in 
patients attending a pacemaker follow-up clinic we have previously 
demonstrated a prevalence of heart failure symptoms with LVSD of 27%.[11] 
 
One third of all pacemaker procedures are to replace an expired existing 
pacemaker generator, and this proportion is increasing.[12] These patients 
might be at even higher risk for underlying LVSD and heart failure in view of 
their older age, longer duration of RV pacing, and underlying cardiac disease. 
The time of a pulse generator replacement (PGR) presents an opportunity to 
review symptoms, LV function, medical therapy and device prescription, but 
this is rarely done.[13] We therefore undertook this pragmatic prospective 
observational study to assess the prevalence and associations of LV 
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dysfunction in patients with long-term RV pacemakers booked for an elective 
generator replacement. 
 
Methods 
All individuals listed for elective pacemaker generator replacement at Leeds 
General Infirmary between 1st March 2008 and 1st December 2011 were 
invited to attend the cardiology department at least one week prior to the 
procedure. We did not enrol patients with implantable cardioverter 
defibrillators (ICDs) or patients with cardiac resynchronisation devices and we 
also excluded patients with congenital structural heart disease (but not those 
with congenital heart block). A series of variables including height, weight, 
blood pressure, symptomatic status (New York Heart Association category), 
medical therapy (including bisoprolol-equivalent beta-blocker dose [14]), past 
medical and cardiac history, the date of first implantation and indication and 
the number of subsequent pacemaker generator replacements were 
recorded. The implant indication was confirmed by reviewing the baseline 
electrocardiograph tracings and the medical records. The pacemaker was 
interrogated to document programming and the percentage of right atrial and 
RV paced (%VP) beats over the preceding twelve months. Previous data 
have suggested an increased risk of hospitalisation for heart failure with >80% 
VP (for VVI pacing) and 40% for DDDR pacing.[6] 
 
A 12-lead electrocardiogram was recorded in each individual to measure QRS 
duration during a paced beat (achieved by shortening the AV delays in those 
with preserved conduction). Each patient underwent a full echocardiographic 
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examination (Vivid 9, Vingmed, USA). We used an LVEF of <50% measured 
E\WKH6LPSVRQ¶VELSODQHPHWKRGVaveraged from three consecutive beats as 
our cut-off for LVSD.[15] In those without important neuromuscular, skeletal, 
pulmonary, and other conditions precluding exercise testing, formal symptom-
limited treadmill-based peak cardiopulmonary exercise testing was carried out 
to establish peak oxygen consumption (Medgraphics, USA), and heart rate 
and blood pressure responses to exercise. A single blood draw was 
performed either at this visit or immediately prior to the procedure to measure 
renal function and blood count.  
 
For hospitalisation and mortality we chose a censor date of 31st December 
2011 and all patients who attended the assessment were included in the final 
analysis. Morbid status and hospitalisation were established from written and 
electronic records and communications with local general practitioners and 
the diagnosis at admission or cause of death recorded.  
 
Data analysis was undertaken using SPSS version 18. Relationships between 
variables were explored initially using simple regression and subsequently by 
multiple regression. Differences between groups were explored using 
6WXGHQW¶V W-test and a Cox proportional hazard model was used to compute 
the hazard ratio and corresponding 95% confidence intervals for subsequent 
mortality or hospitalisation for heart failure. Normally distributed continuous 
data are presented as means (95% confidence intervals (CI)). For continuous 
variables without normal distribution, identified by the Shapiro-Wilk test, we 
have presented median and interquartile range (IQR). We also used %VP 
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transformed to a categorical variable and analysed with an interaction test and 
ANOVA to identify at which category of VP there was a reduced LVEF. 
Predictive model calibration and discrimination was assessed using Hosmer-
Lemeshow and receiver operating characteristic (ROC) curve assessment, 
respectively. The study was approved by the Leeds West Research Ethics 
Committee (08/H1307/12). 
 
Results 
Of the 508 patients undergoing pacemaker generator replacement in the 
study period, we collected a complete dataset on 491 (97%). Patients not 
assessed (or in whom data-points were missing) were not different in terms of 
age, pacemaker variables or co-morbidities. Table 1 shows demographic and 
basic pacemaker data. Cardiovascular co-morbidities (43% had overt 
ischæmic heart disease, 27% atrial fibrillation and 13% diabetes mellitus) and 
concurrent cardiovascular medical therapies were common.  
 
DEVICE PRESCRIPTION AND PROGRAMMING 
Table 2 summarises the nature of the devices and their programming. All 
patients¶ right ventricular leads were in the apical position. Patients in sinus 
rhythm were more likely to have a dual chamber device in situ than patients in 
atrial fibrillation (93 v 49%; p<0.0001), but there was no age difference 
between those with and without dual chamber devices. The most common 
indication for pacemaker implantation was sinus node disease (57%), with 
42% having an indication of atrio-ventricular conduction delay (AV-delay) 
including 27% of the total with third degree block (complete heart block 
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(CHB)) at baseline (table 1). Patients receiving a pacemaker for CHB at 
baseline had a higher %VP at the time of PGR (85 (79-91) v 50 (46-54)%; 
p<0.0001) than those without CHB at baseline, and although 78% of those 
with CHB at baseline had >80%VP at PGR, 12% had less than 40%VP at 
follow-up. Furthermore, 37% of patients implanted for AV block but not CHB 
at baseline were receiving >80%VP at the time of PGR.  
 
There was a weak correlation between age and %VP, (r=0.1; p=0.014) and 
patients with >80%VP were older. There was no correlation between the 
presence of cardiovascular co-morbidities (myocardial infarction, 
percutaneous coronary angioplasty, hypertension, or cardiac surgery), seen in 
50% of the population, and the %VP. On the other hand, there was a 
relationship between %VP and renal function, (r=0.20; p=0.0077) and 
furosemide requirements (r=0.2; p<0.02), and patients with >80%VP at PGR 
had significantly worse renal function (eGFR 53 (49-57) v 60 (56-64); p=0.01). 
 
Rate response mode was more commonly activated in patients with atrial 
fibrillation (66 v 41%; p<0.0001), and was associated with a higher %VP in 
single chamber (but not in dual chamber) devices (%VP 78 (70-86) v 59 (45-
73)%; p=0.009). As a consequence patients with single chamber devices 
experienced a higher %VP than those with dual chamber devices (71 (67-75) 
v 53 (50-56)%; p=0.0002). 
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ECHOCARDIOGRAPHIC AND CARDIOPULMONARY EXERCISE RESULTS 
Table 2 shows the results of non-invasive testing in patients attending for 
PGR. The mean and median LVEF were both 50% and the range was 12-
74%. An interaction plot demonstrated that mean LVEF was only significantly 
lower in patients with %VP>80% so we used this as our cut off for further 
analyses. The prevalence of LV dysfunction (LVEF<50%) was 40% in our 
cohort, but this was significantly higher in those with i) >80%VP (59%) 
compared with <80%VP (22%)(p<0.0001) and ii) those with cardiovascular 
co-morbidities (figure 1). Patients with LV systolic dysfunction were more 
likely to be taking ȕ-blockers (79 v 47%; p<0.0001) and ACE-inhibitors (or 
angiotensin receptor blockers)(83 v 63%; p<0.0001)), although, daily doses 
were suboptimal (mean bisoprolol equivalent 4.5 (0.5)mg, with only 10% on 
the maximal bisoprolol-equivalent dose) and only 16% on an aldosterone 
receptor antagonist. 
 
Patients with CHB at baseline had worse mean LV function at PGR than 
those without baseline CHB (LVEF 46 (44-48) v 52 (50-54)%; p=0.0008, ȋ2 for 
LVEF<50%=7.6; p=0.006). However, the difference in LVEF between those 
with and without >80%VP at PGR were more significant (LVEF 55 (53-57) v 
46 (44-DQGȋ2 for LVEF<50%=48; p<0.0001).  
 
Simple regression suggested relationships between LVEF and age (r=0.15 
p=0.006), %VP at PGR (r=0.40; p<0.0001), serum creatinine (r=0.26; 
p<0.0001), paced QRS width (r=0.41; p=0.0003), and furosemide dose 
(r=0.32; p=0.0001). In a multivariable model only %VP at PGR, serum 
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creatinine and previous myocardial infarction remained significant (table 3). 
These three variables gave a c-statistic of 0.79 (0.72-0.86) and a negative 
predictive value of 89% with a 20% risk cut-off for identifying the presence of 
LVEF<50%. Figure 2 shows the ROC curve for predicting LVEF <50% using 
two variables easily available at every review: %VP at PGR and a history of 
previous myocardial infarction. Using these two variables alone, our model 
has a negative predictive value of 90%, a positive predictive value of 51%, 
with a c-statistic of 0.74 (0.68-0.81)(Hosmer Lemeshow p-value of 0.95).  
 
Peak oxygen consumption (pVO2) was available in 159 (33%) patients. 
Patients with pacemakers have significantly limited exercise capacity, which is 
lowest in those with the highest amount of ventricular pacing (>80%VP) (pVO2 
15 (13-17) v 20 (18-22) ml/kg/min; p=0.0001). In multiple regression analysis, 
peak oxygen consumption was related to age, renal function and furosemide 
requirement rather than any marker of pacemaker activity.  
 
OUTCOME DATA 
We included all patients seen in our correlative analyses, but excluded 25 
patients enrolled into a randomised study of upgrade to cardiac 
resynchronisation therapy in our prospective analysis of outcome. This left a 
population of 466 with the same mean baseline characteristics as the original 
population. After a mean follow-up time of 668 (19) days, 56 patients (12%) 
were dead (n=34) or had been hospitalised (n=22) for heart failure. 
Univariable predictors of mortality or hospitalisation for heart failure are shown 
in Table 4. On multivariable analysis, previous myocardial infarction and high 
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%VP were independently associated with a worse survival. The Kaplan Meier 
curves for patients with and without LVEF <50% and with and without 
%VP>80% are shown in Figure 3.  
 
Discussion 
The present data, the first to explore systematically a contemporary cohort of 
patients undergoing standard pacemaker generator replacement, 
demonstrate a high prevalence of LV dysfunction and cardiovascular co-
morbidity and a mortality rate only modestly lower than that of heart failure 
patients of similar age.[14] The presence of LV dysfunction is independently 
related to the amount of RV pacing and, particularly when combined with a 
high percentage of ventricular pacing, LV dysfunction portends an adverse 
prognosis. 
 
In retrospective analyses [16][17] and one prospective study [9] of patients 
receiving new pacemakers, the most consistent feature predicting outcome 
was LVSD at baseline although age, coronary artery disease, co-morbidities 
(chronic airways disease and diabetes mellitus), paced QRS (for subsequent 
hospitalisation),[18] and atrio-ventricular block are also associated with a 
worse outcome. In our cohort pacing mode or indication was not relevant 
once %VP and the presence of LV dysfunction had been taken into account. 
 
We have been able to construct a model based upon simple pacemaker-
related and clinical variables (>80%VP and previous myocardial infarction) 
that has a negative predictive value of 90% for LVSD and a c-statistic of 0.74 
JCM Jan 19th 2014; Version R1.0 
Gierula et al; Prevalence of LVSD in PGR patients   Page 11 of 19 
(0.68-0.81). This would form an easy way to select patients who might benefit 
from a more extensive review, although whether such a review and the effects 
of interventions undertaken upon identifying LVSD impacts subsequent 
outcomes in this population requires further work. 
  
Aetiology of RV pacing-associated left ventricular dysfunction 
RV pacing induces ventricular dyssynchrony,[19] similar to that seen in 
intrinsic left bundle branch block (LBBB),[20][21] which leads to altered 
regional blood flow and wall stress, increased cardiac sympathetic activity,[4] 
and left ventricular dysfunction directly related to the duration of ventricular 
pacing.[22] Hence, RV apical pacing could either induce LV dysfunction or 
accentuate pre-existing latent LV dysfunction. Which features identify patients 
at high risk of future LV dysfunction is unclear.  
 
Management of RV-pacing associated LV dysfunction 
Studies exploring the medical management of patients with pacemakers and 
LV dysfunction are rare,[23] and although patients with pacemakers and heart 
failure were not excluded from all trials of medical therapy, subgroup analysis 
of the paced population was not undertaken in any of the large studies. For 
example whether, in a patient with LVSD and a pacemaker, the benefit of 
high-GRVH ȕ-blockers compensates for the adverse effects of ventricular 
pacing is unknown. 
 
Since RV pacing contributes to poorer outcomes,[24] reducing this might 
improve LV function or prevent further deterioration. Although >80%VP in VVI 
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mode and >40%VP in DDD mode are associated with an increased rate of 
hospitalisation for heart failure,[6] it is unknown whether there is a target of 
%VP below which the risk of subsequent or deteriorating LVSD is low and 
whether this is different in patients with established LVSD. Reducing RV 
pacing in patients with existing RV pacemakers can improve LV systolic 
dysfunction [25] and reduce the incidence of atrial 
arrhythmias.[26][27][28][29][30] 
 
Reprogramming is not an option in heart failure patients with standard 
pacemakers with complete heart block or a slow response to atrial fibrillation. 
These patients frequently receive an upgrade procedure to cardiac 
resynchronisation therapy (CRT). It is thought that this leads to similar 
improvements in clinical variables and measures of LV function as with de-
novo CRT implants.[20][31][32][33] 
 
Upgrading to CRT at the time of PGR those patients with a high percentage of 
pacing and LV systolic dysfunction (LVEF<50%) but few symptoms improves 
quality of life, LV function, and exercise capacity while reducing NT-pro-B-type 
natriuretic peptide, and might reduce heart failure events,[34] but larger 
studies are required to provide data on hard endpoints. A registry of 
successful upgrades, although useful, is not enough.[35] 
 
Preventing RV pacing-associated LV dysfunction  
Our findings also have implications for the use of µSURSK\ODFWLF¶ CRT in 
patients requiring rate support. Complete heart block (CHB) at baseline only 
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modestly predicts high %VP at long term follow-up, yet 65% of patients with 
AV node disease but without CHB at implant go on to >80%VP. Hence CHB 
at baseline represents only 80% of those eventually requiring >80%VP.[36] 
Also, despite high %VP, some patients in our cohort seem resistant to the 
adverse effects of RV apical pacing. Since CRT at baseline does not 
universally prevent a deterioration in LV function,[37] the benefits of 
prophylactic CRT versus RV pacing in an unselected population may be 
marginal,[38] requiring careful risk stratification to identify patients in whom 
CRT for bradycardia is cost- and clinically-effective. The Biventricular versus 
Right Ventricular Pacing in Heart Failure Patients with Atrioventricular Block 
(BLOCK HF) study,[39] set out to determine whether CRT for bradycardia is 
better than standard RV pacing in patients with mild LVSD (EF<50%). 
Patients receiving biventricular pacing had lower rates of death from any 
cause, urgent heart failure care or increase in left ventricular end systolic 
volume index (LVESI) of >15% from baseline. However, the study included 
patients with an existing CRT indication (30% had LVEF<35% and mean 
QRS duration was 125ms), IRUZKRPµVWDQGDUGFDUH¶PHDQWhigh rates of RV 
pacing with the additional upfront higher risk of a CRT pacemaker 
implantation. Some patients may have experienced more adverse events 
than would be expected with a dual chamber pacemaker programmed to 
avoid pacing. The lack of a control arm (all patients received a CRT device 
with the LV lead deactivated in those randomised to standard RV pacing) 
means that cost-benefit and cost-utility analyses cannot be done.[40] One 
large randomised study looking at the effects on morbidity and mortality of 
CRT versus RV pacemaker systems in patients with a bradycardia has 
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completed recruitment.[41] Although there is growing enthusiasm for right 
ventricular septal pacing there are as yet no hard endpoint data to support 
widespread adoption of this strategy.[42][36] 
 
Limitations 
The present data do not include patients with new implants that did not 
survive to generator replacement, and therefore represent a selected 
SRSXODWLRQ+RZHYHUHYHQWKHVHµVXUYLYRUV¶KDYHDQDSSUHFLDEOHVXEVHTXHQW
morbidity and mortality so a generator replacement procedure might be an 
appropriate time point to review medical and device therapy.  
 
Merely diagnosing the presence of LVSD might have led to changes in 
therapy and programming and therefore outcomes. A future study might 
EHQHILWIURPUDQGRPLVDWLRQWRSURYLGHDFRKRUWRIµXVXDOFDUH¶patients who do 
not undergo echocardiography.  
 
We also excluded from our analysis of survival, the 25 patients with LVSD 
and high %VP that consented to be enrolled into a study of cardiac 
resynchronisation versus standard generator replacement. This might have 
served to reduce the degree of morbidity and mortality associated with high 
amounts of RV pacing and LVSD in our cohort. 
 
By demonstrating a dose-response relationship between the amount of 
ventricular pacing and the degree of LV dysfunction, we have fulfilled one of 
the requirements for causality.[43] We appreciate that we do not have 
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echocardiographic data on our patients at the time of their first pacemaker 
implantation. Hence we cannot comment on whether, and in what 
circumstances, RV pacing induces LV dysfunction. Our stated aim was not 
however, to identify features at baseline that predict future LVSD, rather our 
aim was to provide a platform with which to stratify risk in order to identify 
those patients with existing pacemakers in whom further investigation might 
be of most benefit.  
 
Our dataset and the analysis, although prospectively collected cannot 
account for unknown confounders and our findings along with our risk model 
require validation and refining in future larger internal and external cohorts.   
 
Conclusions 
Patients with RV pacemaker systems listed for elective generator replacement 
have a high prevalence of left ventricular systolic dysfunction strongly 
correlated with the amount of RV pacing to which they are exposed. Those 
with left ventricular systolic dysfunction and high amounts of RV pacing are at 
high risk of subsequent mortality. Simple variables (the presence of >80% VP 
and a previous myocardial infarction) can identify patients who might benefit 
from a more comprehensive review including echocardiography around the 
time of generator replacement but whether there are benefits of optimising 
medical and device therapy in pacemaker patients with cardiac dysfunction 
requires further investigation.  
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